摘要
（目的）评价乐铂单药治疗恶性肿瘤的疗效，同时观察其毒副反应。（方法）并入选肺癌病人105例，包括非小细胞肺．癌（NSCLC）48例、小细胞肺癌（SCLC）57例。应用单药乐铂50mg／m2静脉滴注，每3周1个疗程，平均治疗2个疗程。（结果）非小细胞肺癌患者，4例PR，有效率8．3％，小细胞肺癌患者，1例CR，23例PR，有效率为421％。白细胞下降Ⅰ～Ⅱ级为37.1％，Ⅲ级为8．7％；血小板下降Ⅰ～Ⅱ组为33．9％，Ⅲ级为11．9％；血色素下降Ⅰ～Ⅱ级为12．9％，Ⅲ级为41％；胃肠道毒性Ⅰ～Ⅱ级为43．4％，Ⅲ级为4．6％。（结论）乐铂对小细胞肺癌的疗效较好。主要剂量限制性毒性为骨髓毒性，特别是血小板减少。乐铂直接的肾毒性不明显。
[Purpose] To study the efficasy and adverse effects of using Iobaplatin to treat small cell and non-small cell lungcancer. [Methods] One hundred and five patients with histologically proven SCLC and NSCLC received single agent therapy bylobaplatin 50 mg/m2 iv drip, repeat every 3 weeks and average 2 cycles were given. [Results] Out of 48 NSCLC, 4 PR, RR 8. 3%were observed and out of 57 SCLC, 1 CR, 23 PR, RR 42. 1 % were observed. The main adverse effects (Ⅲ /N grade) wereleukopenia(8. 7 % ), thrombocytopenia (11. 9%), erythrocytopenia(4. 1 % ), vomiting(4. 6 % ). [Conclusioll] Lobaplatin is effectivein treating SCLC. The main dosage litheting toxicity of lobaplatin is myelotoxicity, especially thrombocytopenia. No obviotisnephrotoxicity was observed.
关键词
乐铂
肺肿瘤
药物疗法
毒副反应
治疗
Lobaplatin Lung neoplasms Drug therapy Adverse effect
